July 5 (Reuters) - Trillium Therapeutics Inc TRIL.TO
* Trillium provides update on small molecule programs
* Trillium -concluded that TTI-2341 appears to be a viable and competitive drug candidate for treatment of brain cancers and brain metastases
* Trillium Therapeutics Inc says plans to continue to pursue internal development of TTI-2341 while undertaking partnering discussions in parallel
* Trillium Therapeutics Inc says has launched a discovery program that is focussed on an undisclosed early-stage immuno-oncology target Source text for Eikon: ID:nMKW40dcsa Further company coverage: TRIL.TO